NCT06558682View on ClinicalTrials.gov

Neoadjuvant Therapy in Cervical Cancer

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 20, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
Uterine Cervical Neoplasms
Interventions
DRUG

Disitamab Vedotin and Cisplatin

Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
collaborator

RemeGen Co., Ltd.

INDUSTRY

lead

Qilu Hospital of Shandong University

OTHER